Table 3.

Treatment related changes in lumbar TBS

First author	Year Published	Location	Study design	Subjects	TBS change/yr	Versus baseline	Versus other Rx	BMD change/yr	Versus baseline	Versus other Rx
Krieg [50]	2013	Canada	Case-control	534 PM women on standard OP Rx 1150 untreated	0.20% −0.30%	p < 0.001 p < 0.001	p < 0.001	1.90% −0.40%	p < 0.002 p < 0.001	p < 0.001
Popp [53]	2013	Switzerland	RCT	54 PM women on zoledronate 53 on placebo	0.50% −0.20%	p < 0.001 p < 0.001	p < 0.001	3.20% 0.50%	p < 0.001 p < 0.001	p < 0.001
Senn [59]	2014	Switzerland	Open-Label	65 PM women on teriparatide 122 PM women on ibandronate	2.20% 0.20%	p < 0.001 p = 0.86	p < 0.001	3.80% 1.50%	p < 0.001 p < 0.001	p < 0.001
Kalder [49]	2014	Germany	RCT substudy	17 PM women on tamoxifen 19 PM women on exemestane	1.70% −1.20%	p < 0.06 p < 0.05	p < 0.001	1.00% −2.70%	NS p < 0.002	p < 0.001
Petranova [58]	2014	Bulgaria	Observational	36 PM women on denosumab no controls	1.70%	p < 0.05	NA
Kalder [57]	2015	Germany	RCT	34 women with breast cancer on zoledronate 36 women with breast cancer on placebo	2.41% −0.52%	p<0.006	p=0.003	2.17% −5.02%	p<0.001	p<0.005
Di Gregorio [56]	2015	Spain	Open-Label	67 untreated 87 men and women on calcium and vitamin D 88 men and women on Alendronate 36 men on Testosterone 39 men and women on Risedronate 43 men and women on Denosumab 30 men and women on Teriparatide	−1.55% 0.65% 0.70% 0.90% 0.70% 1.40% 1.80%	p<0.05 NS p<0.05 NS NS p<0.01 p<0.01	NA NA NA NA NA NA	0.25% 0.80% 2.05% 2.20% 2.40% 4.40% 4.40%	NS NS p<0.001 p<0.001 p<0.001 p<0.001 p<0.001	NA NA NA NA NA NA

PM = postmenopusal; NA = not applicable